Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news

Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2
WEDNESDAY, Jan. 13, 2021 -- A candidate vaccine, Ad26.COV2.S, with a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized severe acute respiratory syndrome coronavirus 2 spike protein is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2021 Category: Pharmaceuticals Source Type: news

AskBio taps industry vet for C-suite role in wake of Bayer deal
Fresh off of its acquisition by Bayer AG, Research Triangle Park-based Asklepios BioPharmaceutical Inc. has created a new C-suite position and tapped an industry veteran to fill it. Dr. Katherine High has been named president of therapeutics at AskBio and will also serve on its board of directors. She will be responsible for driving the strategic direction and execution of the company’s preclinical and clinical programs. AskBio, a clinical-stage adeno-associated virus (AAV ) gene therapy company,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 13, 2021 Category: Pharmaceuticals Authors: Cameron Snipes Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Bharat Biotech to start Phase-1 trials of COVID-19 intranasal vaccine in Feb-March
Besides Covaxin, BharatBiotech has been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose intranasal vaccine for COVID-19. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 8, 2021 Category: Pharmaceuticals Source Type: news

South Africa to get 1.5 million COVID-19 vaccines from India
The vaccine, developed with the University of Oxford, is made from a virus which is a weakened version of a common cold virus (adenovirus), that has been genetically changed so that it is impossible for it to grow in humans. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 7, 2021 Category: Pharmaceuticals Source Type: news

More COVID-19 Vaccines Are in the Pipeline as the U.S. Effort Ramps Up
A huge U.S. study of another COVID-19 vaccine candidate got underway Monday as states continue to roll out scarce supplies of the first shots to a nation anxiously awaiting relief from the catastrophic outbreak. Public health experts say more options in addition to the two vaccines now being dispensed — one made by Pfizer and its German partner BioNTech, the other by Moderna — are critical to amassing enough shots for the country and the world. The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the United States. Some 30,000 volunteers are needed to prove if the shot — a diffe...
Source: TIME: Health - December 29, 2020 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

Gene therapy for placental insufficiency moves toward the clinic
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 15, 2020 Category: Biology Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Doctors warn side effects from COVID-19 vaccine "won't be a walk in the park"
(Natural News) Fevers, sweats, migraines and muscle aches that last for days – these are just some of the symptoms reported by various ‘Phase 3’ trial participants who volunteered for the vaccine trials run by Pfizer, Moderna and others. Though AstraZeneca noted in its preliminary results that its vaccine (which uses the more traditional adenovirus vector) seemed... (Source: NaturalNews.com)
Source: NaturalNews.com - November 26, 2020 Category: Consumer Health News Source Type: news

Engineered " stealth bomber " virus could be new weapon against metastatic cancer
(Emory Health Sciences) Researchers at Emory and Case Western Reserve have re-engineered an oncolytic adenovirus. The resulting virus is not easily caught by parts of the innate immune system, making systemic delivery possible without arousing a massive inflammatory reaction. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2020 Category: Cancer & Oncology Source Type: news

AstraZeneca's COVID-19 vaccine will "never be licensed in the US," says analyst
(Natural News) Because its trial designs do not meet even the basic minimum criteria set forth by the Food and Drug Administration (FDA) for new vaccines, AstraZeneca’s adenovirus-vector vaccine for the Wuhan coronavirus (COVID-19) will “never be licensed in the U.S.,” says SVB Leerink health-care analyst George Porges. Despite claims that the jab is 70... (Source: NaturalNews.com)
Source: NaturalNews.com - November 25, 2020 Category: Consumer Health News Source Type: news

Chimpanzee Adenovirus COVID - 19 Vaccine Promising in Seniors
Immunogenicity similar across age groups; vaccine better tolerated in older versus younger adults (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Gynecology, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Chimpanzee Adenovirus COVID-19 Vaccine Promising in Seniors
MONDAY, Nov. 23, 2020 -- The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online Nov. 18 in The Lancet. Maheshi N. Ramasamy, D.Phil., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK
Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen's Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 18, 2020 Category: Consumer Health News Source Type: news

Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
RARITAN, N.J., November 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for inherited retinal disease X-linked retinitis pigmentosa (XLRP). The data showed that low and intermediate doses were well-tolerated and continued to demonstrate statistically significant sustained or increased vision improvement across multiple metrics (mean sensitivity, volumetric and pointwise) and modalities (full-field static perimetry and microperimetry). Data on the novel adeno-associated virus re...
Source: Johnson and Johnson - November 13, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers use bovine adenovirus to develop novel COVID-19 vaccine
(Penn State) A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle. With support from a nearly $3.9 million grant from the National Institutes of Health, the team aims to create a vaccine that will protect all segments of the population, especially older adults. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 7, 2020 Category: Infectious Diseases Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients' cells, provoking a robust immune response. But will pre-existing immunity from common colds take... (Source: The Scientist)
Source: The Scientist - September 8, 2020 Category: Science Tags: News & Opinion Source Type: news

Johnson & Johnson announces that Janssen's COVID-19 investigational vaccine candidate prevents severe clinical disease in pre-clinical studies
Janssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published in Nature Medicine, demonstrated that the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccineJanssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe (Source: World Pharma News)
Source: World Pharma News - September 7, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Toxicity of dorsal root ganglia is widely associated with CNS AAV gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news

Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - August 25, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations Source Type: news

Small change makes cancer vaccine more effective in animal tests
(Thomas Jefferson University) Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2020 Category: International Medicine & Public Health Source Type: news

StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2020 -- (Healthcare Sales & Marketing Network) -- StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith ... Biopharmaceuticals, Personnel StrideBio , gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2020 Category: Pharmaceuticals Source Type: news

CDC Warns Parents To Be On Lookout For Acute Flaccid Myelitis In Children
(CNN) — Parents and pediatricians need to be on the lookout in the coming months for a rare, paralyzing condition that affects young children, the Centers for Disease Control and Prevention said Tuesday. The polio-like condition, called acute flaccid myelitis or AFM, tends to peak every other year, and the last surge of cases was in 2018, when 238 cases were diagnosed across the US, the CDC said. Read: Acute Flaccid Myelitis Fact Sheet This year is likely to see another upsurge but things will be complicated by the coronavirus pandemic. “AFM is a priority for CDC as we prepare for a possible outbreak this ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 5, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Featured Health Syndicated CBSN Boston Acute Flaccid Myelitis CNN Source Type: news

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
NEW BRUNSWICK, N.J., July 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical s...
Source: Johnson and Johnson - July 30, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study. (Source: World Pharma News)
Source: World Pharma News - July 30, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Chimpanzee Adenovirus-Vectored Vaccine Promising for COVID-19
FRIDAY, July 24, 2020 -- A chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein has acceptable safety and induces antibody and T-cell immune responses,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2020 Category: Pharmaceuticals Source Type: news

Ad5-Vectored COVID-19 Vaccine Immunogenic in Healthy Adults
THURSDAY, July 23, 2020 -- The nonreplicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine appears safe and induces immune responses at a dose of 5 ×1010 viral particles, according to a study published online July 20 in The Lancet. Feng-Cai... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2020 Category: Pharmaceuticals Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oxford ’s COVID-19 Vaccine Candidate Takes a Big Leap Forward, Showing Success in Early Trials
The foot race to develop the first effective vaccine against COVID-19 involves an awfully crowded field, with 137 candidate vaccines in pre-clinical study worldwide and another 23 actually in development. But a leader seemed to emerge today with research published in the Lancet reporting promising results in a robust study by investigators at Oxford University in England. The study began in April, with a sample group of 1,077 adults aged 18 to 55—an age group young enough to tolerate exposure to SARS-CoV2, the virus that causes COVID-19, with less risk of adverse effects than would be seen in older, more vulnerable a...
Source: TIME: Health - July 20, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Report: Members of Russia ’s ‘Business and Political Elite’ Have Been Receiving Experimental COVID-19 Vaccine
(Bloomberg) — Scores of Russia’s business and political elite have been given early access to an experimental vaccine against COVID-19, according to people familiar with the effort, as the country races to be among the first to develop an inoculation. Top executives at companies including aluminum giant United Co. Rusal, as well as billionaire tycoons and government officials began getting shots developed by the state-run Gamaleya Institute in Moscow as early as April, the people said. They declined to be identified as the information isn’t public. The Gamaleya vaccine, financed by the state-run Russian D...
Source: TIME: Health - July 20, 2020 Category: Consumer Health News Authors: Stepan Kravchenko, Yuliya Fedorinova and Ilya Arkhipov / Bloomberg Tags: Uncategorized COVID-19 News Desk russia wire Source Type: news

Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Click to Access Audio Press ReleaseRARITAN, NJ, July 17, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today six-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of the investigational adeno-associated virus retinitis pigmentosa GTPase regulator (AAV-RPGR) were generally well-tolerated and indicated significant improvement in vision. Initial data on the novel AAV-RPGR asset, jointly developed with Meir...
Source: Johnson and Johnson - July 17, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Invisible defence against adenoviruses
(Technical University of Munich (TUM)) An adenovirus infection can be potentially life-threatening, especially for children after a stem cell transplant. Virologists at the Technical University of Munich (TUM) and the German Research Center for Environmental Health Helmholtz Zentrum M ü nchen have successfully shown that a previously approved medication used in cancer treatment could help inhibit this virus infection. Due to the special mechanism of action, the virus cannot develop defence strategies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2020 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vac...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene ther...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

Human Adenovirus 7d Strains Associated With Flu-Like Illness Human Adenovirus 7d Strains Associated With Flu-Like Illness
In this report, human adenovirus 7d strains isolated from patients with influenza-like illness were examined. What have we learned?Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2020 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer
BALA CYNWYD, Pa., June 1, 2020 -- (Healthcare Sales & Marketing Network) -- SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neu... Biopharmaceuticals, Neurology, Personnel SwanBio Therapeutics, adeno-associated virus, adrenomyeloneuropathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Exploiting viruses to attack cancer cells
(Hokkaido University) Hokkaido University scientists have made an adenovirus that specifically replicates inside and kills cancer cells by employing special RNA-stabilizing elements. The details of the research were published in the journal Cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Adenovirus Type - 5 Vectored COVID - 19 Vaccine Shows Promise
ELISA antibodies and neutralizing antibodies increased at day 14, peaked at day 28 (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 26, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Adenovirus Type-5 Vectored COVID-19 Vaccine Shows Promise
TUESDAY, May 26, 2020 -- A recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine is safe, tolerable, and immunogenic, according to a study published online May 22 in The Lancet. Feng-Cai Zhu, Ph.D., from the Jiangsu Provincial Center for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2020 Category: Pharmaceuticals Source Type: news

Two Boston Hospitals Team Up In ‘Urgent’ Race To Create Coronavirus Vaccine
BOSTON (CBS) – Two Boston hospitals are teaming up in the race to find a cure for the coronavirus pandemic. Researchers at Massachusetts Eye and Ear and Massachusetts General Hospital are working together to develop a vaccine using a unique gene-based strategy. Their research is using what’s called AAV technology, or Adeno-Associated-Virus technology, in hopes of stimulating the immune system to fight SARS-CoV-2 – the virus responsible for COVID-19. “We’re taking a virus called AAV, that’s harmless and has been engineered to be harmless, and we’re using it essentially as a delivery...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 5, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Syndicated Local Coronavirus Mass Eye And Ear Mass General Hospital Source Type: news

Massachusetts Eye and Ear, Mass General advancing novel gene-based COVID-19 vaccine, AAVCOVID
(Massachusetts Eye and Ear Infirmary) A unique COVID-19 genetic vaccine program is underway with Mass. Eye and Ear and Mass General Hospital, member hospitals of Mass General Brigham. The AAVCOVID vaccine program is the only gene-based vaccine approach for COVID-19 that uses adeno-associated virus (AAV), a harmless viral vector, as a delivery vehicle for inducing an immune response. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 5, 2020 Category: Infectious Diseases Source Type: news

High-resolution CT improves pulmonary nodule evaluation
Japanese researchers have found that boosting the matrix size for high-resolution...Read more on AuntMinnie.comRelated Reading: AI aids classification of indeterminate lung nodules Panel: CT lung screening can be delayed during COVID-19 CT findings for coronavirus may overlap with adenovirus X-ray may be missing COVID-19 cases found with CT Risk model predicts malignancy of lung nodules on CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 4, 2020 Category: Radiology Source Type: news

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. (Source: World Pharma News)
Source: World Pharma News - April 30, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news